ЧТО МЫ ЗНАЕМ О БЕЗОПАСНОСТИ ИНТРАНАЗАЛЬНЫХ КОРТИКОСТЕРОИДОВ?
https://doi.org/10.15690/vsp.v11i2.224
Аннотация
Анализ 62 литературных источников и клинических исследований, основанных на принципах доказательной медицины, позволил авторам статьи заключить, что современные интраназальные глюкокортикостероиды обладают хорошим профилем безопасности и могут широко использоваться для лечения аллергических и воспалительных заболеваний носа и околоносовых пазух как у взрослых, так и у детей.
Об авторе
В. В. Шиленкова
Ярославская государственная медицинская академия
Россия
Россия
Шиленкова Виктория Викторовна, доктор медицинских наук, профессор кафедры оториноларингологии ГБОУ «Ярославская государственная медицинская академия» Минздравсоцразвития РФ
Список литературы
1. Гущин И. С. Аллергическое воспаление и его фармакологический контроль. М.: Фармарус принт. 1998. 252 c.
2. Гущин И. С., Ильина Н. И., Польнер С. А. Аллергический ринит: методическое пособие. Москва. 2002. 68 с.
3. Карпова Е. П. Лечение аллергического ринита у детей. М.: ГЭОТАР-Медиа. 2007. 192 с.
4. Stjarne P. et al. A randomized controlled trial of mometasone furoate nasal spray for the treatment of nasal polyposis. Arch. Otolaryngol. Head Neck Surg. 2006; 132 (2): 179–185.
5. Benninger M. S., Ahmad N., Marple B. F. The safety of intranasal steroids. Otolaryngol. Head Neck Surg. 2003; 129: 739–750.
6. Demoly P. Safety of intranasal corticosteroids in acute rhinosinusitis. Am. J. Otolaryngol. 2008; 29 (6): 403–413.
7. Small C. B. Efficacy and safety of mometasone furoate nasal spray in nasal polyposis. J. Allergy Clin. Immunol. 2005; 116 (6): 1275–1281.
8. Penagos M. et al. Efficacy of mometasone furoate nasal spray in the treatment of allergic rhinitis. Meta-analysis of randomized, double-blind, placebo-controlled, clinical trials. Allergy. 2008; 63 (10): 1280–1291.
9. Given J. T. Fluticasone furoate nasal spray is effective and well tolerated for perennial allergic rhinitis in adolescents and adults. Am. J. Rhinol. Allergy. 2010; 24 (6): 444–450.
10. Klossek J. M. Efficacy and safety of mometasone furoate nasal spray in the treatment of sinusitis or acute rhinosinusitis. Rev. Laryngol. Otol. Rhinol. 2007; 128 (3): 187–192.
11. Jankowski R. et al. Long-term study of fluticasone propionate aqueous nasal spray in acute and maintenance therapy of nasal polyposis. Allergy. 2009; 64 (6): 944–950.
12. Mabry R. L. Intranasal steroid injection during pregnancy. South Med. J. 1980; 73: 1176–1179.
13. Meltzer E. O., Bachert C., Staudinger H. Treating acute rhinosinusitis: comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo. Allergy Clin. Immunol. 2005; 116 (6): 1289–1295.
14. Anolik R. Mometasone furoate improves nasal and ocular symptoms of seasonal allergic rhinitis in adolescents. Allergy Asthma Proc. 2009; 30 (4): 406–412.
15. Benninger M. et al. Evaluating approved medications to treat allergic rhinitis in the United States: an evidence-based review of efficacy for nasal symptoms by class. Ann. Allergy Asthma Immunol. 2010; 104 (1): 13–29.
16. Rosenblut A. Long-term safety of fluticasone furoate nasal spray in adults and adolescents with perennial allergic rhinitis. Allergy. 2007; 62 (9): 1071–1077.
17. Martin B. G. Optimal dose selection of fluticasone furoate nasal spray for the treatment of seasonal allergic rhinitis in adults and adolescents. Allergy Asthma Proc. 2007; 28: 216–225.
18. Гаращенко Т. И. Лечение аллергических ринитов у детей. Вестник оториноларингологии. 2005; 3: 66–69.
19. Berlucchi M., Tomenzoli D. Intranasal steroid therapy in inflammatory nasal-sinus pathology in pediatric age. Minerva Pediatr. 2009; 61 (3): 323–331.
20. Demain J. C., Goetz D. W. Pediatric adenoidal hypertrophy and nasal airways obstruction: reduction with aqueous nasal beclomethasone. Pediatrics. 1995; 95 (3): 355–364.
21. Cengel S., Akyol M. U. The role of nasal steroids in treatment of children with otitis media with effusion and/or adenoid hypertrophy. Int. J. Pediatr. Otorhinolaryngol. 2006; 70: 639–645.
22. Small P. et al. A comparison of triamcinolone acetonide nasal aerosol spray and fluticasone propionate aqueous solution spray in the treatment of spring allergic rhinitis. J. Allergy Clin. Immunol. 1997; 100 (5): 592–595.
23. Davies R. J., Nelson H. S. Once-daily mometasone furoate nasal spray: efficacy and safety of a new intranasal glucocorticoid for allergic rhinitis. Clin. Ther. 1997; 19 (1): 27–38.
24. Herman H. Once-daily administration of intranasal corti costeroids for allergic rhinitis: a comparative review of efficacy, safety, patient preference, and cost. Am. J. Rhinol. 2007; 21: 70–79.
25. Cingi C., Songu M. Nasal steroid perspective: knowledge and attitudes. Eur. Arch. Otorhinolaryngol. 2010; 267 (5): 725–730.
26. Brown H. M., Storey G., Jackson F. A. Beclomethasone dipropionate aerosol in treatment of perennial and seasonal rhinitis: a review of five years' experience. Br. J. Clin. Pharmacol. 1977; 4 (Suppl. 3): 283–286.
27. Jacobs R. et al. Effectiveness of fluticasone furoate 110 microg once daily in the treatment of nasal and ocular symptoms of seasonal allergic rhinitis in adults and adolescents sensitized to mountain cedar pollen. Curr. Med. Res. Opin. 2009; 25 (6): 1393–1401.
28. Toogood J. H. Efficacy of safety of concurrent use of intranasal flunisolide and oral beclomethasone aerosols in treatment of asthmatics with rhinitis. Clin. Allergy. 1982; 12 (1): 95–105.
29. Luskin A. T. Is there a role for aerosol nasal sprays in the treatment of allergic rhinitis: a white paper? Allergy Asthma Proc. 2011; 32 (2): 168–177.
30. Wilson A. M. Effects of intranasal corticosteroids on adrenal, bone, and blood markers of systemic activity in allergic rhinitis. J. Allergy Clin. Immunol. 1998; 102: 598–604.
31. Zhuang H., Wen W. Clinical observation on intranasal budesonide in chronic nonallergic rhinitis. Lin. Chuang Er. Bi. Yan. Hou. Ke. Za. Zhi. 2006; 20 (2): 67–69.
32. Weinstein S. et al. Efficacy and safety of triamcinolone acetonide aqueous nasal spray in children aged 2 to 5 years with perennial allergic rhinitis: a randomized, double-blind, placebo-controlled study with an open-label extension. Ann. Allergy Asthma Immunol. 2009; 102 (4): 339–347.
33. Gawchik S. M., Saccar C. L. A risk-benefit assessment of intranasal triamcinolone acetonide in allergic rhinitis. Drug Saf. 2000; 23 (4): 309–322.
34. Schenkel E. J. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics. 2000; 105: 22.
35. Pitsios C. Efficacy and safety of mometasone furoate vs nedocromil sodium as prophylactic treatment for moderate/severe seasonal allergic rhinitis. Ann. Allergy Asthma Immunol. 2006; 96 (5): 673–678.
36. Tripathy I. et al. HPA axis safety of fluticasone furoate nasal spray once daily in children with perennial allergic rhinitis. Pediatr. Allergy Immunol. 2009; 20 (3): 287–294.
37. Agertoft L. Nasal powder administration of budesonide for seasonal rhinitis in children and adolescents. Ped. Allergy Immunol. 1993; 4: 152–156.
38. Vaidyanathan S., Barnes M., Lipworth B. J. Comparative safety and efficacy of 2 formulations of fluticasone aqueous nasal spray in persistent allergic rhinitis. Ann. Allergy Asthma Immunol. 2009; 102 (1): 76–83.
39. Galant S. P. Lack of effect of fluticasone propionate aqueous nasal spray on the hypothalamic-pituitary-adrenal axis in 2- and 3-year-old patients. Pediatrics. 2003; 112 (1): 96–100.
40. Skoner D. A. et al. Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. Pediatrics. 2000; 105: 23.
41. Baena-Cagnani C. E. Safety and tolerability of treatments for allergic rhinitis in children. Drug Saf. 2004; 27 (12): 883–898.
42. Zitt M., Kosoglou T., Hubbell J. Mometasone furoate nasal spray: a review of safety and systemic effects. Drug Saf. 2007; 30 (4): 317–326.
43. Keles N. Treatment of allergic rhinitis during pregnancy. Am. J. Rhinol. 2004; 18 (1): 23–28.
44. Suissa S. et al. Inhaled and nasal corticosteroids use and the risk of fracture. Am. J. Respir. Crit. Care Med. 2004; 169: 83–88.
45. Clissold S. P., Heel R. C. Budesonide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in asthma and rhinitis. Drugs. 1984; 28 (6): 485–518.
46. Mosges R. et al. Efficacy and safety of Mometasone Furoate nasal spray in the treatment of chronic rhinosinusitis. Adv. Ther. 2011; 28 (3): 238–249.
47. Bekowitz R. B. Mometasone furoate nasal spray is rapidly effective in the treatment of seasonal allergic rhinitis in an outdoor (park), acute exposure setting. Allergy and Asthma Proc. 1999; 20: 167–172.
48. Berlucchi M. Pedruzzi B. Intranasal Mometasone Furoate for treatment of allergic rhinitis. Therapeutics. 2010; 2: 761–769.
49. Baena-Cagnani C. E., Patel P. Efficacy and long-term safety of mometasone furoate nasal spray in children with perennial allergic rhinitis. Curr. Med. Res. Opin. 2010; 26 (9): 2047–2055.
50. Jacobs R. et al. Weather/temperature-sensitive vasomotor rhinitis may be refractory to intranasal corticosteroid treatment. Allergy Asthma Proc. 2009; 30 (2): 120–127.
51. Berg O., Lie K., Steinsvag S. The effect of decongestive nosedrops on human respiratory mucosa in vitro. Laryngoscope. 1994; 104: 1153–1158.
52. Hofmann T., Wolf G., Koidl B. In vitro Untersuchungen uber die Wirkung vasokonstriktorischer Nasentropfen auf das Flimmerepithel der menschlichen Nasenschleimhaut. Laryngol. Rhinol. Otol. 1995; 74: 564–567.
53. Minshall E. et al. Assessment by nasal biopsy of long-term of mometasone furoate aqueous nasal spray (Nasonex) in the treatment of perennial rhinitis. Otolaryngol. Head Neck Surg. 1998; 118: 648–654.
54. Devillier P. Pharmacology of glucocorticoids and ENT pathology. Presse Med. 2001; 30: 59–69.
55. Cervin A., Andersson M. Intranasal steroids and septum perforation — an overlooked complication? A description of the course of events and a discussion of the causes. Rhinology. 1998; 36: 128–132.
56. Курбачева О. М., Ильина Н. И. Лечение аллергического ринита: когда, как и зачем? Рос. аллергол. журнал. 2006; 2: 71–80.
57. Dibildox J. Safety and efficacy of mometasone furoate aqueous nasal spray in children with allergic rhinitis: results of recent clinical trials. J. Allergy Clin. Immunol. 2001; 108: 54–58.
58. Ratner P. H., Meltzer E. O., Teper A. Mometasone furoate nasal spray is safe and effective for 1-year treatment of children with perennial allergic rhinitis. Int. J. Pediatr. Otorhinolaryngol. 2009; 73 (5): 651–657.
59. Schafer T. et al. Therapeutic Index (TIX) for intranasal corti co steroids in the treatment of allergic rhinitis. Rhinology. 2011; 49: 1–9.
60. Desrosiers M. et al. Intranasal corticosteroid use is associated with lower rates of bacterial recovery in chronic rhinosinusitis. Otolaryngol. Head Neck Surg. 2007; 136 (4): 605–609.
Рецензия
Для цитирования:
Шиленкова В.В. ЧТО МЫ ЗНАЕМ О БЕЗОПАСНОСТИ ИНТРАНАЗАЛЬНЫХ КОРТИКОСТЕРОИДОВ? Вопросы современной педиатрии. 2012;11(2):122-126. https://doi.org/10.15690/vsp.v11i2.224
For citation:
Shilenkova V.V. WHAT DO WE KNOW ABOUT THE SAFETY OF NASAL CORTICOSTEROIDS? Current Pediatrics. 2012;11(2):122-126. (In Russ.) https://doi.org/10.15690/vsp.v11i2.224
Просмотров: 710
Послать статью по эл. почте 
